Literature DB >> 1443310

A quality-of-life method for estimating the value of avoided morbidity.

M T French1, J A Mauskopf.   

Abstract

We developed a quality-of-life method for valuing changes in health status. Our model determines changes in health attributes for different illnesses and then estimates the dollar value of the corresponding welfare losses. We used our quality-of-life approach to estimate willingness to pay to avoid asthma, a headache, a cough, bronchitis, and arthritis. Estimates derived using our method are similar to those obtained from more expensive and restrictive traditional methods.

Entities:  

Mesh：

Year:  1992        PMID： 1443310      PMCID： PMC1694602          DOI： 10.2105/ajph.82.11.1553

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


  4 in total

1.  Estimating the full cost of workplace injuries.

Authors:  M T French
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

2.  Willingness to pay and accept risks to cure chronic disease.

Authors:  M S Thompson
Journal:  Am J Public Health       Date:  1986-04       Impact factor: 9.308

3.  A scale of valuations of states of illness: is there a social consensus?

Authors:  R Rosser; P Kind
Journal:  Int J Epidemiol       Date:  1978-12       Impact factor: 7.196

4.  Estimating the value of avoiding morbidity and mortality from foodborne illnesses.

Authors:  J A Mauskopf; M T French
Journal:  Risk Anal       Date:  1991-12       Impact factor: 4.000
  4 in total
  6 in total

Review 1.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

2.  Quality-of-life measures in asthma--do they matter to the GP?

Authors:  K Gruffydd-Jones
Journal:  Br J Gen Pract       Date:  1997-06       Impact factor: 5.386

3.  Economic and outcomes assessment of magnetic resonance imaging in the evaluation of headache.

Authors:  J E Jordan; G F Ramirez; W G Bradley; D Y Chen; J B Lightfoote; A Song
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

4.  Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.

Authors:  J A Mauskopf; S C Cates; A D Griffin; D M Neighbors; S C Lamb; C Rutherford
Journal:  Pharmacoeconomics       Date:  2000-06       Impact factor: 4.981

Review 5.  NSAIDs and the elderly. Toxicity and economic implications.

Authors:  A C Phillips; R P Polisson; L S Simon
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

6.  The cost of crime to society: new crime-specific estimates for policy and program evaluation.

Authors:  Kathryn E McCollister; Michael T French; Hai Fang
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.